{"id":273,"date":"2026-04-28T23:07:28","date_gmt":"2026-04-29T06:07:28","guid":{"rendered":"https:\/\/taurusmeds.com\/articles\/trt-acute-kidney-injury\/"},"modified":"2026-04-28T23:07:32","modified_gmt":"2026-04-29T06:07:32","slug":"trt-acute-kidney-injury","status":"publish","type":"post","link":"https:\/\/taurusmeds.com\/articles\/trt-acute-kidney-injury\/","title":{"rendered":"TRT and Acute Kidney Injury What Recent Safety Reviews Show"},"content":{"rendered":"<style>\n  a, a:visited { color: #F1471D !important; }\n  .section-spacing { margin: 28px 0 !important; }\n  .toc ol { margin-left: 1.25rem; }\n  .toc li { margin: 6px 0; }\n<\/style>\n<section class=\"section-spacing\">\n<h2 class=\"wp-block-heading\">TRT and Acute Kidney Injury What Recent Safety Reviews Show<\/h2>\n<\/section>\n<section class=\"section-spacing\">\n<p><strong>Estimated reading time:<\/strong> ~10 minutes<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-key-takeaways\">Key takeaways<\/h3>\n<ul class=\"wp-block-list\">\n<li>A modest AKI signal has emerged in higher-risk men on TRT, with low absolute rates (roughly a 1\u20132% absolute difference over several years).<\/li>\n<li>TRAVERSE and real-world cohorts show elevated AKI risk, while other observational work is neutral\u2014underscoring uncertainty and the value of monitoring.<\/li>\n<li>Early therapy (3\u20136 months), obesity, diabetes, and hypertension appear to mark higher risk; blood pressure and hematocrit are key safety levers.<\/li>\n<li>No hydration \u201cthreshold\u201d prevents AKI, but steady hydration and avoidance of dehydration during illness, heat, or intense training are prudent.<\/li>\n<li>Shared decision-making and a structured safety plan help preserve TRT benefits while managing kidney risk.<\/li>\n<\/ul>\n<\/section>\n<section class=\"section-spacing toc\">\n<h3 class=\"wp-block-heading\" id=\"h-toc\">Table of contents<\/h3>\n<ol class=\"wp-block-list\">\n<li><a href=\"#h-overview\">Overview: Acute kidney injury signals in TRT users<\/a><\/li>\n<li><a href=\"#h-latest-evidence\">What the latest evidence shows<\/a><\/li>\n<li><a href=\"#h-mechanisms\">How might TRT influence kidney risk?<\/a><\/li>\n<li><a href=\"#h-closer-monitoring\">Who may need closer monitoring?<\/a><\/li>\n<li><a href=\"#h-practical-monitoring\">Practical monitoring for renal safety on TRT<\/a><\/li>\n<li><a href=\"#h-hydration-lifestyle\">Hydration and lifestyle considerations<\/a><\/li>\n<li><a href=\"#h-oral-vs-injectable\">Oral vs injectable TRT: Any difference for the kidneys?<\/a><\/li>\n<li><a href=\"#h-unknowns\">What we still don\u2019t know<\/a><\/li>\n<li><a href=\"#h-taurus-approach\">How Taurus Meds approaches renal safety<\/a><\/li>\n<li><a href=\"#h-conclusion\">Conclusion<\/a><\/li>\n<\/ol>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-overview\">Overview: Acute kidney injury signals in TRT users<\/h3>\n<p>Testosterone replacement therapy (TRT) is increasingly prescribed for symptomatic hypogonadism, and its cardiovascular safety has been studied intensively. Less discussed\u2014but important for men weighing risks and benefits\u2014is kidney safety. Recent evidence, including secondary outcomes from the TRAVERSE randomized trial and newer real-world analyses, suggests a small increase in acute kidney injury (AKI) among certain TRT users. This article unpacks what that signal means, who it might affect most, and how practical monitoring and hydration habits can support safer therapy.<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-latest-evidence\">What the latest evidence shows<\/h3>\n<p>Two types of studies inform the current view of TRT kidney injury risk: randomized trial data and observational real-world cohorts.<\/p>\n<ul class=\"wp-block-list\">\n<li><strong>TRAVERSE randomized controlled trial:<\/strong> In men with hypogonadism and high cardiovascular risk, AKI occurred in 2.3% of those assigned to TRT vs 1.5% with placebo (P=0.04). Although AKI was a secondary outcome and the trial was not powered specifically for renal endpoints, the difference was statistically significant and prompted attention to renal safety alongside other non-MACE signals (like atrial fibrillation and pulmonary embolism).<\/li>\n<li><strong>Real-world cohort data (Journal of Sexual Medicine, 2025\u20132026):<\/strong> A multi-year analysis of 4,268 hypogonadal men found AKI in 3.5% of TRT users vs 2.3% of non-users over approximately three years (P=0.018; relative risk 1.53, 95% CI 1.07\u20132.18). TRT users in this study had more cardiometabolic comorbidity at baseline (e.g., higher rates of obesity and diabetes), which could partly explain the difference but does not fully negate the signal.<\/li>\n<\/ul>\n<p>Context matters. Absolute AKI rates remained low in both studies, and the observed risk increase translates to a modest absolute difference (around 1\u20132% over several years in higher-risk men). Notably, some broader observational studies (outside high-risk cohorts) report neutral or slightly lower AKI risk with TRT, highlighting how baseline risk, selection criteria, and confounding can alter findings. Taken together, the data suggest TRT kidney injury risk is small but real in certain populations and warrants routine kidney- and blood-pressure\u2013focused monitoring.<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-mechanisms\">How might TRT influence kidney risk?<\/h3>\n<p>Potential contributors to AKI risk on TRT include:<\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Blood pressure effects:<\/strong> Ambulatory blood pressure monitoring in clinical reviews of oral testosterone undecanoate formulations demonstrated average increases in blood pressure. Even small sustained BP rises can increase renal workload, particularly in men with pre-existing hypertension or CKD risk.<\/li>\n<li><strong>Erythrocytosis and viscosity:<\/strong> TRT can raise hematocrit. Higher blood viscosity may, in theory, reduce renal microcirculatory reserve during dehydration or acute illness. Hematocrit above 54% is a recognized threshold to pause or adjust therapy.<\/li>\n<li><strong>Volume status:<\/strong> Dehydration from illness, heat exposure, or intense training\u2014especially when combined with diuretics or NSAIDs\u2014can precipitate AKI. If TRT also nudges blood pressure or hematocrit upward, this may further narrow the margin for error.<\/li>\n<li><strong>Underlying comorbidity:<\/strong> Obesity, diabetes, and hypertension are common in men seeking TRT and independently increase AKI risk. The real-world study found higher rates of these conditions among TRT users, which may amplify vulnerability.<\/li>\n<li><strong>Mechanisms still uncertain:<\/strong> There is no consensus on a direct nephrotoxic effect of testosterone at physiologic replacement doses. The signal could reflect hemodynamic changes, susceptibility in at-risk men, or residual confounding in observational designs.<\/li>\n<\/ul>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-closer-monitoring\">Who may need closer monitoring?<\/h3>\n<p>Based on the trials, regulatory reviews, and real-world patterns, closer renal safety monitoring is especially relevant for:<\/p>\n<ul class=\"wp-block-list\">\n<li>Men with obesity (BMI \u226530), diabetes, or hypertension<\/li>\n<li>Those with borderline renal function at baseline or a history of AKI<\/li>\n<li>Early in therapy (first 3\u20136 months), when many physiologic adjustments occur<\/li>\n<li>Users of medications that influence renal perfusion (e.g., ACE inhibitors\/ARBs, diuretics) or nephrotoxic agents (e.g., frequent NSAID use), particularly during illness or dehydration<\/li>\n<li>Men on formulations associated with blood pressure increases or men who have rising hematocrit on therapy<\/li>\n<\/ul>\n<p>None of these factors automatically disqualify someone from TRT, but they raise the value of baseline assessment and scheduled follow-up.<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-practical-monitoring\">Practical monitoring for renal safety on TRT<\/h3>\n<p>While protocols vary, a cautious, patient-centered monitoring approach can help detect issues before they become problems.<\/p>\n<ul class=\"wp-block-list\">\n<li><strong>Before starting:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Confirm hypogonadism with appropriate testing and review comorbidities.<\/li>\n<li>Baseline labs: serum creatinine and eGFR; hematocrit\/hemoglobin; blood pressure assessment. Consider urinalysis if CKD risk is present.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Early follow-up:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Recheck renal function and blood pressure at approximately 3\u20136 months after initiation or dose adjustment.<\/li>\n<li>Monitor hematocrit; many programs pause or modify therapy if hematocrit exceeds 54%.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Ongoing surveillance:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Annual kidney function and hematologic monitoring for lower-risk men; more frequent checks if CKD, diabetes, hypertension, or rising hematocrit is present.<\/li>\n<li>Encourage home blood pressure tracking, especially for those on oral testosterone undecanoate or with borderline office readings.<\/li>\n<\/ul>\n<\/li>\n<li><strong>Red flags prompting clinician contact:<\/strong>\n<ul class=\"wp-block-list\">\n<li>A sustained, unexplained rise in creatinine or drop in eGFR compared with baseline<\/li>\n<li>New or worsening hypertension, headaches, or edema<\/li>\n<li>Symptoms of possible AKI (e.g., reduced urine output, flank pain, severe fatigue), especially during or after acute illness, dehydration, or use of nephrotoxic medications<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>These steps are not a substitute for individualized medical care; they reflect the themes emphasized in trial findings and regulatory reviews focused on BP and hematologic effects.<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-hydration-lifestyle\">Hydration and lifestyle considerations<\/h3>\n<p>No trial has established that hydration \u201cprevents\u201d TRT kidney injury, and no evidence-based intake threshold has been defined. Still, basic hydration and recovery habits matter for kidney health, especially in men with comorbidities.<\/p>\n<ul class=\"wp-block-list\">\n<li>Aim for consistent day-to-day hydration; adjust upward during heat, heavy training, fever, or gastrointestinal illness.<\/li>\n<li>Discuss sick-day plans with your clinician if you take medications that can affect kidney blood flow (e.g., diuretics, ACE inhibitors\/ARBs). Avoiding dehydration plus high-dose NSAIDs during illness is often prudent.<\/li>\n<li>Moderate alcohol; minimize unnecessary NSAID use.<\/li>\n<li>Support blood pressure control through nutrition, sleep, and activity. Weight reduction in men with obesity can benefit BP, glycemic control, and renal workload\u2014and may improve TRT response.<\/li>\n<li>Keep dosing steady and avoid supraphysiologic peaks. Staying within therapeutic ranges helps limit hematocrit rise and blood pressure shifts.<\/li>\n<\/ul>\n<p>Again, these are general kidney-friendly practices. They complement, but do not replace, lab monitoring and clinician oversight.<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-oral-vs-injectable\">Oral vs injectable TRT: Any difference for the kidneys?<\/h3>\n<p>Large head-to-head renal safety comparisons between injectable and oral formulations are limited. However:<\/p>\n<ul class=\"wp-block-list\">\n<li>Regulatory reviews for oral testosterone undecanoate approvals emphasized blood pressure increases on ambulatory monitoring and rises in hematocrit. Neither review highlighted a specific AKI signal in phase 3 programs.<\/li>\n<li>Because blood pressure and hematocrit can influence renal risk, men on any formulation should have these parameters tracked. For oral TU, BP monitoring deserves special attention given the observed average increases.<\/li>\n<li>In the real-world AKI analysis, formulation-specific kidney outcomes were not the primary focus. The overall pattern suggests patient factors (obesity, diabetes, hypertension) may carry as much or more weight than formulation choice.<\/li>\n<\/ul>\n<p><strong>Bottom line:<\/strong> choose a formulation with your clinician that achieves physiologic replacement and is practical for adherence and monitoring, then follow a structured safety plan.<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-unknowns\">What we still don\u2019t know<\/h3>\n<ul class=\"wp-block-list\">\n<li><strong>Causality and mechanisms:<\/strong> Is the AKI signal driven by BP changes, hematocrit-related viscosity, unmeasured confounding, or a direct renal effect?<\/li>\n<li><strong>Timing:<\/strong> Are the first 3\u20136 months the highest-risk window, and does risk plateau thereafter?<\/li>\n<li><strong>Long-term outcomes:<\/strong> How does AKI risk evolve beyond three years, and does TRT influence chronic kidney disease progression differently across risk groups?<\/li>\n<li><strong>Prevention strategies:<\/strong> Can tailored hydration, careful NSAID use, and BP optimization measurably reduce AKI risk on TRT, and by how much?<\/li>\n<li><strong>Best monitoring cadence:<\/strong> What follow-up schedule maximizes safety while minimizing burden in varied risk profiles?<\/li>\n<\/ul>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-taurus-approach\">How Taurus Meds approaches renal safety<\/h3>\n<ul class=\"wp-block-list\">\n<li>We start with a thorough baseline evaluation, including renal function, hematocrit, and blood pressure.<\/li>\n<li>Early follow-up at 3\u20136 months helps catch trends in eGFR, creatinine, BP, and hematocrit.<\/li>\n<li>We individualize surveillance intensity for men with obesity, diabetes, hypertension, or early CKD.<\/li>\n<li>Patients receive practical guidance on hydration, sick-day considerations, and when to contact the care team.<\/li>\n<li>We coordinate with primary care and cardiometabolic specialists when needed to align goals and reduce polypharmacy risks.<\/li>\n<\/ul>\n<p>This approach aims to preserve the benefits of TRT while managing the small but meaningful risk of kidney injury.<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-conclusion\">Conclusion<\/h3>\n<p>The best current evidence suggests a modest increase in AKI among higher-risk men on TRT, with low absolute event rates. TRAVERSE and real-world data align in signaling an elevated risk, while other observational work indicates the story may be more nuanced in broader populations. Until more definitive answers arrive, practical steps\u2014baseline assessment, early and periodic monitoring of renal function, blood pressure, and hematocrit, plus attention to hydration and comorbidities\u2014offer a balanced path forward.<\/p>\n<p>For men considering TRT or already on therapy, the question is not \u201cIs TRT safe for kidneys?\u201d but rather \u201cWhat is my personal kidney risk, and how will we monitor and manage it?\u201d With structured oversight and shared decision-making, most men can navigate TRT kidney injury concerns thoughtfully and safely.<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-disclaimer\">Disclaimer<\/h3>\n<p>This article is for educational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional about your specific health circumstances.<\/p>\n<\/section>\n<section class=\"section-spacing\">\n<h3 class=\"wp-block-heading\" id=\"h-sources\">Sources<\/h3>\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41817467\/\" target=\"_blank\" rel=\"noopener\">PubMed: TRAVERSE secondary outcomes (AKI signal)<\/a><\/li>\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/208088Orig1s000SumR.pdf\" target=\"_blank\" rel=\"noopener\">FDA Summary Review (2023): Testosterone undecanoate (oral) approval dossier<\/a><\/li>\n<li><a href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/206089Orig1s000MedR.pdf\" target=\"_blank\" rel=\"noopener\">FDA Medical Review (2019): Jatenzo (testosterone undecanoate) clinical review<\/a><\/li>\n<li><a href=\"https:\/\/academic.oup.com\/jsm\/article-abstract\/21\/12\/1201\/7863208\" target=\"_blank\" rel=\"noopener\">Journal of Sexual Medicine (2025\u20132026): Real-world AKI analysis in TRT users<\/a><\/li>\n<\/ul>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>TRT and Acute Kidney Injury What Recent Safety Reviews Show Estimated reading time: ~10 minutes Key takeaways A modest AKI signal has emerged in higher-risk men on TRT, with low absolute rates (roughly a 1\u20132% absolute difference over several years). TRAVERSE and real-world cohorts show elevated AKI risk, while other observational work is neutral\u2014underscoring uncertainty [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-273","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/comments?post=273"}],"version-history":[{"count":1,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/273\/revisions"}],"predecessor-version":[{"id":274,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/posts\/273\/revisions\/274"}],"wp:attachment":[{"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/media?parent=273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/categories?post=273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/taurusmeds.com\/articles\/wp-json\/wp\/v2\/tags?post=273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}